95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine

2004 ◽  
Vol 40 ◽  
pp. 34 ◽  
Author(s):  
P. Marcellin ◽  
G.K.K. Lau ◽  
F. Bonino ◽  
P. Farci ◽  
S. Hadziyannis ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Blind Study ◽  
Phase Iii ◽  
Double Blind Study ◽  
Double Blind ◽  
Lamivudine Monotherapy ◽  
Peginterferon Alfa ◽  
Negative Chronic Hepatitis

scholarly journals Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B

Hepatology ◽  
2008 ◽  
Vol 49 (4) ◽  
pp. 1141-1150 ◽  
Author(s):  
Maurizia Rossana Brunetto ◽  
Francesco Moriconi ◽  
Ferruccio Bonino ◽  
George K. K. Lau ◽  
Patrizia Farci ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Surface Antigen ◽  
Sustained Response ◽  
Virus Surface ◽  
B Virus ◽  
Peginterferon Alfa ◽  
Negative Chronic Hepatitis

scholarly journals No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B

PLoS ONE ◽  
2018 ◽  
Vol 13 (7) ◽  
pp. e0199198 ◽  
Author(s):  
Lai Wei ◽  
Heiner Wedemeyer ◽  
Yun-Fan Liaw ◽  
Henry Lik-Yuen Chan ◽  
Teerha Piratvisuth ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Il28b Genotype ◽  
Peginterferon Alfa ◽  
Negative Chronic Hepatitis
Sign in / Sign up

Export Citation Format

Share Document